Experiences with
Tofacitinib55 public posts
Want to take advantage of all our features? Just log in!
or
Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database
• New disproportionality signals with a pharmacologically plausible mechanism in bone fragility were found for drugs used in the fields of neurology (selective 5-HT1 agonists, levodopa and memantine), hematology (romiplostim), pulmonology (macitentan), ophthalmology (ranibizumab), and rheumatology (tofacitinib
What to Know About Getting the Second COVID-19 Vaccine Dose If You’re Immunocompromised or Have an Autoimmune Condition
The American College of Rheumatology recently recommended that some patients can stop taking methotrexate and JAK inhibitors [such as tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq)] for one week after each vaccine dose.
ACR: Vaccinate patients with musculoskeletal, inflammatory, autoimmune disease for COVID-19
.), tofacitinib (Xeljanz, Pfizer) and upadacitinib (Rinvoq, AbbVie) — and some biologics — abatacept (Orencia, Bristol Myers Squibb) and rituximab (Rituxan, Genentech) — that alter the immune system’s response in ways that might affect vaccine response.
Preventing Heart Disease When You Have Rheumatoid Arthritis: Which Tests Do You Need?
JAK inhibitors include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq). IL-6 inhibitors include such as tocilizumab (Actemra) and sarilumb (Kevzara).
Rheumatoid Arthritis and Heart Disease: Why You’re at Increased Risk
TNF inhibitors include adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi and Simponi Aria), and infliximab (Remicade),
Other medications like JAK inhibitors [such as tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) and IL-6 inhibitors [
Rheumatoid Arthritis and Heart Disease: 28 Ways You Can Lower Your Risk
Know that JAK inhibitors and IL-6 blockers might raise cholesterol
JAK inhibitors for RA include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq). Interleukin-6 inhibitors include tocilizumab (Actemra) and sarilumab (Kevzara).